EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Risk Factors for Ventilator-Associated Pneumonia in Patients Ventilated for Non-Pulmonary Conditions: A Prospective Multicenter Cohort Study (PULMIVAP)

Laura Alagna, Liliane Chatenoud, Emanuele Palomba, Ilaria Olgiati, Federico Magni, Leonardo Mancabelli, Francesca Turroni, Chiara Abbruzzese, Chiara Buracchi, Cristina Bugarin, Matteo Filippini, Andrea Forastieri, Giuseppe Gaipa, Roberto Fumagalli, Marina Munari, Antonio Muscatello, Edoardo Picetti, Leonardo Terranova, Rosanna Vaschetto, Tommaso Zoerle, Marco Ventura, Giuseppe Citerio, Andrea Gori, Alessandra Bandera, Federica Sole Golfetto, Anna Tonizzo, Davide Mangioni, Francesca Elli, Silvia Del Bianco, Alessia Vargiolu, Christian Milani, Antonino Panacea, Nicola Latronico, Lorenzo Pilati, Gloria Erbici, Alberto Steffanoni, Martina Viganò, Cristina Panzeri, Daniele Cerani, Fabrizio Ortolano

Open Forum Infectious Diseases · 2026-10-31 · 13 (11)

DOI: 10.1093/ofid/ofag677 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Ventilator-associated pneumonia (VAP) is a frequent complication of invasive mechanical ventilation (IMV), yet its determinants in patients ventilated for non-pulmonary indications remain poorly characterized. Methods Data were derived from the PULMIVAP multicenter prospective cohort (ClinicalTrial: NCT04849039), conducted in 8 Northern Italian intensive care units (January 2021–April 2024). All adults receiving IMV for non-pulmonary indications were enrolled if expected to require IMV >48 hours and antibiotic-free for ≥3 days preceding intubation. Clinical and therapeutic data were collected for up to 15 days of IMV; microbiological sampling was performed according to clinical indication. The primary outcome was time to first VAP within 15 days of IMV (VAP15). Associations between baseline characteristics, time-varying exposures, and VAP15 were evaluated. Thirty-day mortality from IMV initiation was a secondary outcome. Results Among 406 patients, 148 (36%) developed VAP15, at a median of 6 days (IQR 4.0–7.5) with an incidence rate of 43.2 per 1000 ventilator-days at risk (95% confidence intervals [95% CI], 36.4–49.9). Non-neurologic diagnosis (adjusted hazard ratio [aHR] 0.51; 95% CI, 0.31–0.86), female sex (aHR, 0.52; 95% CI, 0.36–0.75), and early antibiotic initiation (days 1–2 of IMV, aHR, 0.65; 95% CI, 0.45–0.93) were independently associated with lower risk of VAP15. Predominant pathogens were Staphylococcus aureus, Klebsiella spp., and Haemophilus influenzae; multidrug-resistant organisms were uncommon. VAP15 showed no competing relationship or significant association with mortality (overall, 20.4%). Conclusions In patients receiving IMV for non-pulmonary indications, non-neurologic diagnosis, female sex, and early antibiotic exposure were associated with lower observed VAP incidence, though causality cannot be inferred. Risk-stratified prevention strategies warrant further investigation into this population.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →